Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi and Regeneron's Dupixent (dupilumab) wins FDA approval for allergic fungal rhinosinusitis following Ph3 success
Antibody, autoimmune, monoclonal antibody, allergic fungal rhinosinusitis, IL-4/IL-13 inhibitor, dupilumab - Read more

Organon, Sebela Pharmaceuticals license hormone-free copper IUD Miudella, $27.5M upfront, $505M milestones
Licensing deal, women's health, medical devices, milestone payments - Read more

Labcorp, PathAI expand partnership to offer AI-powered digital pathology platform AISight Dx nationwide
Partnership expansion, AI/ML, diagnostics, digital pathology, strategic investment - Read more

Evinova, Astellas Pharma, AstraZeneca partner on AI clinical development platform to accelerate trial design
AI/ML, clinical development, research collaboration, digital health - Read more

Pfizer, Sciwind Biosciences partner on Chinese GLP-1 ecnoglutide commercialization, up to $495M deal
Licensing deal, metabolic disease, GLP-1 receptor agonist, milestone payments - Read more

Grünenthal, Clinect partner for exclusive Australian rights to Qutenza topical pain patch
Licensing deal, pain management, topical drug, commercialization - Read more

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

ViiV Healthcare's Dovato (dolutegravir/lamivudine) shows lower steatotic liver disease rates versus Biktarvy in Ph4 trial
Small molecule, infectious disease, antiretroviral therapy, HIV, metabolic comorbidities, combination therapy - Read more

Cadrenal Therapeutics reports encouraging Ph2 results for CAD-1005 targeting heparin-induced thrombocytopenia, reducing thrombotic events
Small molecule, autoimmune, 12-lipoxygenase inhibitor, heparin-induced thrombocytopenia, thrombotic events - Read more

Novo Nordisk's UBT251 shows 19.7% weight loss in Ph2 obesity trial in China
Small molecule, metabolic, obesity, triple-acting mechanism, GLP-1 receptor - Read more

Slate Medicines launches with $130M Series A to advance China-licensed PACAP migraine drug into clinical testing
Neurological, migraine prevention, antibody, clinical-stage - Read more

MiniMed eyes $784M IPO, Medtronic diabetes division spinout with insulin management ecosystem
Diabetes, medical devices, insulin management, continuous glucose monitoring - Read more

Linnaeus Therapeutics awarded $22M ARPA-H contract, advancing LNS8801 for healthspan preservation
Small molecule, diseases of aging, oncology, clinical-stage - Read more

Cambrian Bio awarded $30.8M ARPA-H funding for selective mTORC1 inhibitor development
Clinical-stage, small molecule, aging, metabolic pathways, platform technology - Read more

Turbine raises $25M Series B, virtual biology platform for drug discovery
AI/ML platform, virtual biology, immunology, oncology, drug discovery, platform technology - Read more

QT Sense raises €4M ($4.7M) funding, quantum sensing technology for biomedical research
Quantum sensing, biomarker discovery, oncology, oxidative stress - Read more

Palvella Therapeutics raises $150M public offering, rare skin disease therapies development
Rare disease, clinical-stage, dermatology, vascular malformations - Read more

Novartis settles lawsuit with Henrietta Lacks estate over unauthorized cell use from 1951 biopsy
Cell therapy, oncology, financial, settlement - Read more

Western biopharma licensing deals with Chinese companies surge 230% in upfront values, reaching $172M average
Bispecific antibody, oncology, strategic, major transaction - Read more

Roche seeks production partner for Rocephin antibiotic amid rising Swiss manufacturing costs
Manufacturing agreement, infectious disease, divestment, antibiotics - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Abcuro's ulviprubart (ABC008) fails Ph2/Ph3 trial for inclusion body myositis despite targeting KLRG1 pathway
Antibody, autoimmune, monoclonal antibody, inclusion body myositis, KLRG1 target - Read more

Werewolf Therapeutics explores sale or merger options as cash reserves expected to deplete by Q4
Immunotherapy, oncology, strategic, financial - Read more

FDA's Makary backs mRNA vaccines but ends $500M taxpayer funding, says companies should self-fund research
mRNA vaccine, infectious disease, regulatory, strategic - Read more

Novo Nordisk slashes GLP-1 prices 50% to $675 after losing market share to Lilly
GLP-1 agonist, metabolic disease, competitive, major transaction, cost reduction - Read more

BioMarin pulls hemophilia gene therapy Roctavian from market, taking $240M hit after failed divestiture efforts
Gene therapy, hemophilia, strategic, major transaction, operational - Read more

FDA halts MacroGenics lorigerlimab cancer trial enrollment after patient death from severe side effects
Bispecific antibody, oncology, regulatory, operational, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here